HOTH News and Press, Hoth Therapeutics Inc. From 12/01/22

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 PR Newswire Clinical trial to begin early 2023 for Cancer patients NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused ...

Hoth Therapeutics ( NASDAQ: HOTH ) has regained compliance with Nasdaq's minimum bid price listing requirement. On Dec. 30, 2021, Nasdaq notified the company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business day...

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it receiv...

Clinical-stage biopharmaceutical company Hoth Therapeutics ( NASDAQ: HOTH ) announced Monday that its investigational therapy BioLexa met the primary and secondary endpoints for safety and efficacy in a Phase 1b trial for adults with mild-to-moderate atopic dermatitis (AD). ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Hoth Therapeutics (NASDAQ: HOTH ) stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa . BioLexa is a treatment in development at ...

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS PR Newswire MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACY BIOLEXA led to significant improvement in disease severity as measured by SCOR...

Hoth Therapeutics ( NASDAQ: HOTH ) stock fell ~13% after the bell on Monday after the firm said it will effect a 1-for-25 reverse stock split effective as of Wednesday, Oct. 26. Once the reverse split becomes effective, Hoth Therapeutics ( HOTH ) will have ~1.3M sh...

Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 PR Newswire NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, ann...

Hoth Therapeutics ( NASDAQ: HOTH ) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-t...

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke PR Newswire TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke M...